>
Switch to:

Fate Therapeutics Inventory-to-Revenue

: 0.00 (As of Jun. 2021)
View and export this data going back to 2013. Start your Free Trial

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Fate Therapeutics's Total Inventories for the quarter that ended in Jun. 2021 was $0.00 Mil. Fate Therapeutics's Revenue for the three months ended in Jun. 2021 was $13.41 Mil. Fate Therapeutics's Inventory-to-Revenue for the quarter that ended in Jun. 2021 was 0.00.

Fate Therapeutics's Inventory-to-Revenue for the quarter that ended in Jun. 2021 stayed the same from Mar. 2021 (0.00) to Mar. 2021 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Total Inventories can be measured by Days Sales of Inventory (DSI). Fate Therapeutics's days sales of inventory (DSI) for the three months ended in Jun. 2021 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.


Fate Therapeutics Inventory-to-Revenue Historical Data

The historical data trend for Fate Therapeutics's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fate Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Inventory-to-Revenue
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Fate Therapeutics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Inventory-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Fate Therapeutics's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Fate Therapeutics Inventory-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, Fate Therapeutics's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Fate Therapeutics's Inventory-to-Revenue falls into.



Fate Therapeutics Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Fate Therapeutics's Inventory-to-Revenue for the fiscal year that ended in Dec. 2020 is calculated as

Inventory-to-Revenue (A: Dec. 2020 )
=Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2019 ) + Total Inventories (A: Dec. 2020 )) / count ) / Revenue (A: Dec. 2020 )
=( (0 + 0) / 1 ) / 31.434
=0 / 31.434
=0.00

Fate Therapeutics's Inventory-to-Revenue for the quarter that ended in Jun. 2021 is calculated as

Inventory-to-Revenue (Q: Jun. 2021 )
=Total Inventories / Revenue
=( (Total Inventories (Q: Mar. 2021 ) + Total Inventories (Q: Jun. 2021 )) / count ) / Revenue (Q: Jun. 2021 )
=( (0 + 0) / 1 ) / 13.412
=0 / 13.412
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fate Therapeutics  (NAS:FATE) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Fate Therapeutics's Days Inventory for the three months ended in Jun. 2021 is calculated as:

Days Inventory=Total Inventories (Q: Jun. 2021 )/Cost of Goods Sold (Q: Jun. 2021 )*Days in Period
=0/0*365 / 4
=

2. Total Inventories can be measured by Days Sales of Inventory (DSI).

Fate Therapeutics's Days Sales of Inventory for the three months ended in Jun. 2021 is

Days Sales of Inventory (DSI)=Total Inventories (Q: Jun. 2021 )/Revenue (Q: Jun. 2021 )*Days in Period
=0/13.412*365 / 4
=0.00

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Fate Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2021 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Jun. 2021 ) / Total Inventories (Q: Jun. 2021 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fate Therapeutics Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Fate Therapeutics's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Fate Therapeutics Business Description

Fate Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2836
Traded in Other Exchanges
Address
3535 General Atomics Court, Suite 200, San Diego, CA, USA, 92121
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Executives
Tahl Cindy officer: General Counsel and Secretary C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, STE 200 SAN DIEGO CA 92121
Shoemaker Daniel D officer: Chief Scientific Officer C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, SUITE 200 SAN DIEGO CA 92121
Valamehr Bahram officer: Chief Development Officer C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, STE 200 SAN DIEGO CA 92121
Dulac Edward J Iii officer: Chief Financial Officer FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT STE 200 SAN DIEGO CA 92121
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE BUILDING D, SUITE D3-300 SAN FRANCISCO CA 94129
Green Jeremy director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D SUITE D3-300 SAN FRANCISCO CA 94129
Jooss Karin director C/O GRITSTONE ONCOLOGY, INC. 5858 HORTON STREET, SUITE 210 EMERYVILLE CA 94608
Agarwal Shefali director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Mendlein John director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: MENDLEIN JOHN a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Rastetter William H director 9885 TOWNE CENTRE DR. SAN DIEGO CA 92121
Hershberg Robert director 3005 FIRST AVENUE SEATTLE WA 98121
Coughlin Timothy director 339 NORTH GRANADOS AVE SOLANA BEACH CA 92075
Lee Michael Stewart director C/O REDMILE GROUP, LLC ONE LETTERMAN DR., BLDG. D, SUITE D3-300 SAN FRANCISCO CA 94129
Epstein Robert S director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: EPSTEIN ROBERT S a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Wolchko J Scott director, officer: President and CEO C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, SUITE 200 SAN DIEGO CA 92121

Fate Therapeutics Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)